Clorazepate (Tranxene) Tapering: A Slow, Supervised Approach

What is clorazepate, and why does it last so long in the body?

Clorazepate, sold under the brand name Tranxene, is a long-acting benzodiazepine. Benzodiazepines act on the receptor for gamma-aminobutyric acid (GABA), the brain’s main calming chemical messenger, and every drug in the class can cause physical dependence when it is taken daily for weeks or longer. That dependence is a medical condition, not an addiction, and the second section explains why.

Clorazepate is unusual in one way. It is a prodrug, meaning the drug in the tablet is not the drug that does the work: according to its United States Food and Drug Administration (FDA) label, swallowed clorazepate is converted so quickly to nordiazepam that essentially none of the parent drug circulates, and nordiazepam is what reaches the brain. Nordiazepam is also the main active metabolite of diazepam (Valium), so the two medications behave much alike once they are in the bloodstream.

That metabolite lingers. The label gives nordiazepam a serum half-life of about two days, and Table 1 of the Ashton Manual lists the active metabolite of clorazepate at 36 to 200 hours. So, in the slowest metabolizers it can take more than a week for the level of active drug to fall by half.

The label lists three approved uses: the management of anxiety disorders or the short-term relief of anxiety symptoms, add-on treatment for partial seizures, and the symptomatic relief of acute alcohol withdrawal. Insomnia is not one of them.

Most people who need a clorazepate taper are not addicted to it.

Most people who need to come off clorazepate took it exactly as their doctor prescribed. Over months or years, the brain adapted to the constant presence of nordiazepam at its GABA receptors, and now it cannot work normally without it. That adaptation is physical dependence, and dependence is not addiction.

Addiction involves compulsive use despite harm, and it is rare among people prescribed a benzodiazepine for anxiety. Physical dependence, by contrast, is the expected result of the medication doing what it does. It is a medical condition caused by a prescription, and the right response is a gradual medical taper, not an addiction treatment program.

The 2020 FDA boxed-warning update for the whole benzodiazepine class says as much. It states that physical dependence can develop with continued use even at prescribed doses, and that abrupt discontinuation or rapid dose reduction can bring on withdrawal reactions, some of them life-threatening.

Why is stopping clorazepate abruptly dangerous?

The clorazepate label is blunt on this point. Withdrawal symptoms have occurred after abrupt discontinuance, and the list it gives includes convulsions, tremor, abdominal and muscle cramps, vomiting, sweating, nervousness, insomnia, irritability, and memory impairment. The label adds that after extended use, abrupt discontinuation should generally be avoided and a gradual taper followed.

Chapter II of the Ashton Manual says the same about the class: abrupt or over-rapid withdrawal, especially from high doses, can produce convulsions, psychotic reactions, and acute anxiety states. A long half-life does not remove this risk. It can delay it and soften it: the Maudsley Deprescribing Guidelines note that short-acting benzodiazepines bring more severe acute withdrawal than longer-acting drugs, and because the nordiazepam level falls slowly, the worst symptoms may arrive days after the last tablet.

A seizure is a medical emergency. Anyone who has a seizure, or who develops severe or rapidly worsening symptoms after stopping or cutting a benzodiazepine, should call emergency services (911 in the United States) at once.

Does a clorazepate taper need a crossover to diazepam?

Not always. The Ashton Manual recommends a crossover taper to diazepam for people taking potent, short-acting benzodiazepines such as alprazolam and lorazepam, because their blood levels rise and fall between doses and their tablets cannot be divided finely enough. Clorazepate already delivers a long-acting metabolite that keeps blood levels smooth around the clock. Even so, the Maudsley Deprescribing Guidelines describe two recognized routes off it: a direct taper from clorazepate, or a switch to diazepam.

So, a person taking clorazepate may be tapered directly, on the drug they are already taking, or may be switched to diazepam first. The Guidelines note that the evidence does not settle which route is better, and that the patient’s preference should count.

Where a switch is chosen, the equivalence comes from Table 1 of the Ashton Manual, which lists clorazepate 15 mg as approximately equivalent to diazepam 10 mg. The Manual notes that even some long-acting benzodiazepines may need a switch to diazepam because of limited dose formulations.

Because the two drugs share the same active metabolite, Dr. Leeds decides with each patient whether a crossover would help. His page on the Ashton Manual and the crossover taper explains how he uses it.

How slowly should a clorazepate taper go?

Slowly, and for longer than most doctors expect. Chapter II of the Ashton Manual calls the classic six-week withdrawal schedule much too fast for many people who have taken benzodiazepines long term, and adds that whether a withdrawal takes 6, 12, or 18 months is of little significance for someone who has taken them for years. In Dr. Leeds’ practice, a clorazepate taper usually takes a year to 18 months or longer.

The shape of the taper matters as much as its length. The Maudsley Deprescribing Guidelines describe hyperbolic dose reductions: each step is a proportion of the current dose rather than a fixed number of milligrams, so the steps grow smaller as the dose falls. This reflects how the GABA receptor responds to the drug: the last few milligrams have a far larger effect than the first few removed.

Think of walking down a hill that gets steeper near the bottom. Near the top, a full stride is safe. Near the bottom, the same stride would send you tumbling, so the steps have to shorten.

Because nordiazepam clears so slowly, each reduction needs time before it can be judged. A symptom that appears a week after a cut is often that cut catching up, not a sign that the taper has failed. A hold at the current dose, kept short rather than open-ended, is part of the method, and Professor C. Heather Ashton advised readers to proceed at a comfortable pace and, as far as possible, never to go backwards, though in Dr. Leeds’ practice a small updose to the last steady dose, agreed with the prescriber, is a legitimate decision and not a failure.

How can the steps be made small enough when the tablets come in fixed strengths?

Generic clorazepate tablets come in 3.75 mg, 7.5 mg, and 15 mg strengths, while the brand Tranxene T-Tab is currently supplied only as a 7.5 mg tablet. Early in a taper those strengths are workable. Late in a taper, when the daily dose may be a fraction of one tablet, cutting tablets into quarters produces uneven pieces and steps far too large for a hyperbolic taper.

Compounded liquid formulations solve this. A compounding pharmacy can prepare clorazepate as a liquid in a known concentration, so the dose can be measured with an oral syringe and reduced by tiny amounts. Low-dose compounded capsules are the other option. Either way, the point is the same: the step has to be small enough to measure and small enough to tolerate.

What does a clorazepate taper look like in Dr. Leeds’ practice?

Dr. Leeds is an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida, and his practice focuses on medically supervised tapering off of benzodiazepines and z-drug sleeping pills. He works with each patient directly, by telemedicine or at his Fort Lauderdale office, and there is no facility, no group, and no fixed program length. The practice is concierge, meaning it does not bill insurance, and it serves patients in Florida only.

The first conversation is about informed consent, and it starts with risks. A patient learns what a taper involves, what the alternatives are, including staying at the current dose for now, what the exit plan looks like, and that they may decline or pause at any point without losing his care. Consent is a continuing conversation, not a form.

From there, the patient sets the pace. If a reduction proves too much, Dr. Leeds advises a hold or a smaller step, and if a stretch goes well, patient and doctor may agree to go a bit faster, as tolerated. A taper that takes a year is not a failed taper. It is a taper matched to the nervous system it belongs to.

Three questions people often ask about a clorazepate taper.

Is Tranxene the same as clorazepate?

Yes. Tranxene is the brand name of clorazepate dipotassium, and the T-Tab is the branded tablet. Generic clorazepate tablets contain the same drug and are tapered the same way.

Why do clorazepate withdrawal symptoms show up days after a dose change?

Because the active metabolite, nordiazepam, has a half-life measured in days. A reduction made on a Monday may not be fully felt until the following week, which is why each step is held long enough to be judged before the next one.

What happens if symptoms flare in the middle of a clorazepate taper?

One answer is a short hold at the current dose, then a smaller step, though everybody is different, and some patients do better continuing at a steady pace than waiting out a long hold, so any change is planned with the prescriber and the medication is never stopped suddenly. Professor Ashton advised avoiding a return to a higher dose as far as possible. Still, a small updose, decided case by case with a physician who knows benzodiazepine withdrawal, can be the right step, and the Maudsley Deprescribing Guidelines advise returning to a higher dose if symptoms are severe, waiting for them to settle, and then tapering more slowly. No patient is pushed through a reduction they cannot tolerate. The pace belongs to the patient.

Clorazepate’s long half-life makes it one of the more forgiving benzodiazepines to taper, and patients come off it slowly, either directly or after a switch to diazepam, a choice made with each patient. What they need is a physician who will take the months it requires and let them set the pace. Dr. Leeds’ practice provides medically supervised clorazepate tapering for patients throughout Florida. Contact the office to ask about a consultation.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.